New drug KK2223 enters early human testing for Tough-to-Treat T-Cell lymphoma
NCT ID NCT07192471
First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 3 times
Summary
This early-stage trial is testing an experimental drug called KK2223 in 72 adults with T-cell lymphoma (a type of blood cancer) that has returned or not responded to prior treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. The study is not yet recruiting and will take place at multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KK2223 (an experimental drug given by IV infusion)
- What this could lead to
- If it works, this could point toward a new treatment option for people with T-cell lymphoma that has not responded to other therapies.
- What could go wrong
- This is a very early Phase 1 trial focused on safety and dosing, not on effectiveness. It is small (72 people) and may not lead to a proven treatment. Side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL NHL (PTCL OR CTCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AOU Citta' della Salute e della Scienza di Torino Ospedale Molinette, Ematologia Universitaria
Torino, 10126, Italy
-
Azienda Ospedaliera Papa Giovanni XXIII - Ematologia
Bergamo, 24127, Italy
-
Azienda Ospedaliero Universitaria di Bologna IRCCS (Policlinico di Sant'Orsola) - Ematologia
Bologna, 40138, Italy
-
Beth Israel Deaconess Medical Center - Research
Boston, Massachusetts, 02215, United States
-
Clinica Universidad de Navarra - Hematología
Pamplona, Navarre, 31008, Spain
-
Clinica Universidad de Navarra - Hematología y Hemoterapia
Madrid, 28027, Spain
-
Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division
Hackensack, New Jersey, 07601-2105, United States
-
Hospital Clinic De Barcelona - Hematología
Badalona, Barcelona, 8036, Spain
-
Institut Català d'Oncologia (ICO) - ICO L'Hospitalet - Hematologia
L'Hospitalet de Llobregat, Barcelona, 8907, Spain
-
Istituto di Candiolo, IRCCS - Oncologia Medica ed Ematologia
Candiolo, Torino, 10060, Italy
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021-6007, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Stanford University School of Medicine
Stanford, California, 94305, United States
-
The University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of California, Irvine Medical Center - Hematology/Oncology
Orange, California, 92868, United States
-
University of Pennsylvania - Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
Washington University School of Medicine - Oncology Hospital - Public
St Louis, Missouri, 63110, United States